Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer

Inclusion Criteria:

• Patients who tested positive EBV and confirmed suffering advanced nasopharyngealcancer

• Patients who have partial response or stable disease or progressive disease afterperformed standard therapy (radiology or chemoradiation) based on RECIST

• Did not take traditional medicine in the last 2 months.

• Patients can understand the nature of the study and willing to sign informed consent

• Patients who received standard medical (radiology or chemoradiation) up to oneadditional therapy in the last 1 month.

Exclusion Criteria:

• Patients who are pregnant, planning to pregnant, or breastfeeding

• Patients assessed to require chemoradiation during this study

• Patients who get complete score after undergo standard therapy (radiology orchemoradiation) based on the RECIST

• Patients who have autoimun reaction, eczema, allergy or allergy history, andanaphylaxis

• Patients who have creatinin clearance result <40 ml/min, bilirubin serum >1.5x abovenormal, SGPT-SGOT >5x above normal

• Patients on immunosuppressive medications, such as corticosteroids

• Patients who undergo Major thoracic or abdominal operation

• Patients on high medical risk condition due to uncontrolled infection

• Patients who diagnosed positive of Hepatitis B, Hepatitis C or HumanImmunodeificiency virus (HIV)

• Patients who have concurrent congestive heart failure history and other heartdisease

• Patients who have health conditions assessed by the doctor in charge cannot beincluded in this clinical trial

• Patients who refuse or did not participate in part or all of the research process